MAM
PHAS

Meeder Asset Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Meeder Asset Management’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-294
Closed -$1K – 2615
2020
Q1 		$1K Buy
+294
New +$1.35K ﹤0.01% 2268

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meeder Asset Management's PHAS Position: Q2 2020 in Review

Meeder Asset Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2020, closing a stake of 294 shares — an estimated $1K sold.

Meeder Asset Management first reported a position in PHAS in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 60 funds tracked by Wall St. Rank hold PHAS as of Q2 2020.

  • Meeder Asset Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 294 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $1K.
  • Meeder Asset Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • Meeder Asset Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $1K in Q1 2020.
  • 60 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.